MET and neoplasm: Strikingly, cMet‐positive tumours showed higher percentage of proliferating cells compared to cMet‐negative tumours (26.75% versus 9.33%, P < 0.001; Figs 5D and EV4), while treatment with Tepotinib in cMet‐positive tumours led to a significant reduction in pH3, showing equivalent levels to the cMet‐negative tumours.